Skip to main content
Fig. 5 | BMC Gastroenterology

Fig. 5

From: Effect of skeletal muscle loss during neoadjuvant imatinib therapy on clinical outcomes in patients with locally advanced GIST

Fig. 5

A 3-year survival of pre-treatment sarcopenia versus pre-treatment non-sarcopenia; B 3-year survival between post-treatment sarcopenia and post-treatment non-sarcopenia; C 3-year survival between the appearance of SML and No-SML during neoadjuvant therapy in men. D 3-year survival between the appearance of SML and No-SML during neoadjuvant therapy in women

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us